Dynavax Technologies (DVAX) Stock Price, News & Analysis

Company Overview

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; Biological E. Limited; PT Bio Farma; Medigen Vaccine Biologics; and Serum Institute of India Pvt. Ltd. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. The company was incorporated in 1996 and is headquartered in Emeryville, California.

Key Stats

• Today's Range: $13.42 to $13.83
• 50-Day Range: $12.39 to $13.42
• 52-Week Range: $9.74 to $14.05
• Volume: 828,953 shs
• Average Volume: 1.81 million shs
• Market Capitalization: $1.81 billion
• P/E Ratio: 76.69
• Dividend Yield: N/A
• Price Target: $21.50
• Consensus Rating: Hold

Dynavax Technologies Stock Analysis - MarketRank™

Dynavax Technologies scored higher than 84% of companies evaluated by MarketBeat, and ranked 171st out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.2 / 5
• Analyst Rating: Hold

Consensus Rating

Dynavax Technologies has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 2 buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Dynavax Technologies has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 53.13%

Earnings Growth

Earnings for Dynavax Technologies are expected to grow by 53.13% in the coming year, from $0.32 to $0.49 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Dynavax Technologies is 76.69, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 23.74.

Price to Earnings Ratio vs. Sector

The P/E ratio of Dynavax Technologies is 76.69, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 26.71.

Price to Book Value per Share Ratio

Dynavax Technologies has a P/B Ratio of 2.87. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

14.79% of the outstanding shares of Dynavax Technologies have been sold short.

Short Interest Ratio / Days to Cover

Dynavax Technologies has a short interest ratio ("days to cover") of 9.9.

Change versus previous month

Short interest in Dynavax Technologies has recently increased by 1.41%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Dynavax Technologies does not currently pay a dividend.

Dividend Growth

Dynavax Technologies does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.7 / 5
• Environmental Score: -1.59

Percentage of Shares Shorted

14.79% of the outstanding shares of Dynavax Technologies have been sold short.

Short Interest Ratio / Days to Cover

Dynavax Technologies has a short interest ratio ("days to cover") of 9.9.

Change versus previous month

Short interest in Dynavax Technologies has recently increased by 1.41%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 2.3 / 5
• News Sentiment: 0.13

News Sentiment

Dynavax Technologies has a news sentiment score of 0.13. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.51 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 43 news articles for Dynavax Technologies this week, compared to 4 articles on an average week.

Search Interest

5 people have searched for DVAX on MarketBeat in the last 30 days. This is an increase of 67% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Dynavax Technologies insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 2.98% of the stock of Dynavax Technologies is held by insiders.

Percentage Held by Institutions

96.96% of the stock of Dynavax Technologies is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

DVAX Stock Analysis - Frequently Asked Questions

How have DVAX shares performed this year?

Dynavax Technologies' stock was trading at $12.77 at the start of the year. Since then, DVAX stock has increased by 8.0% and is now trading at $13.7950.
View the best growth stocks for 2025 here.

How were Dynavax Technologies' earnings last quarter?

Dynavax Technologies Co. (NASDAQ:DVAX) announced its earnings results on Thursday, February, 20th. The biopharmaceutical company reported $0.05 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $0.05. The biopharmaceutical company earned $72.03 million during the quarter, compared to the consensus estimate of $72.70 million. Dynavax Technologies had a trailing twelve-month return on equity of 4.22% and a net margin of 9.85%.

Who are Dynavax Technologies' major shareholders?

Top institutional shareholders of Dynavax Technologies include Deep Track Capital LP (13.53%), Vanguard Group Inc. (6.97%), Chicago Capital LLC (4.09%) and Deerfield Management Company L.P. Series C (3.95%). Insiders that own company stock include Andrew A F Hack, Ryan Spencer, Robert Janssen, Francis Cano, David F Novack and Justin Burgess.
View institutional ownership trends.

How do I buy shares of Dynavax Technologies?

Shares of DVAX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Dynavax Technologies own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Dynavax Technologies investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), AUO (AUOTY) and DiamondRock Hospitality (DRH).

Company Calendar

• Last Earnings: 2/20/2025
• Today: 2/26/2025
• Next Earnings (Estimated): 5/14/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:DVAX
• CUSIP: 26815810
• CIK: 1029142
• Web: www.dynavax.com
• Phone: (510) 848-5100
• Fax: 510-848-1327
• Employees: 350
• Year Founded: 1996

Price Target and Rating

• Average Stock Price Target: $21.50
• High Stock Price Target: $31.00
• Low Stock Price Target: $12.00
• Potential Upside/Downside: +60.3%
• Consensus Rating: Hold
• Rating Score (0-4): 2.33
• Research Coverage: 3 Analysts

Profitability

• EPS (Most Recent Fiscal Year): $0.18
• Trailing P/E Ratio: 74.50
• Forward P/E Ratio: 41.91
• P/E Growth: N/A
• Net Income: $-6,390,000.00
• Net Margins: 9.85%
• Pretax Margin: 9.29%
• Return on Equity: 4.22%
• Return on Assets: 2.67%

Debt

• Debt-to-Equity Ratio: 0.33
• Current Ratio: 13.23
• Quick Ratio: 12.34

Sales & Book Value

• Annual Sales: $260.81 million
• Price / Sales: 6.76
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.81 per share
• Price / Book: 2.79

Miscellaneous

• Outstanding Shares: 131,455,000
• Free Float: 127,538,000
• Market Cap: $1.76 billion
• Optionable: Optionable
• Beta: 1.32